Cargando…

Potential diagnostic value of CSF metabolism-related proteins across the Alzheimer’s disease continuum

BACKGROUND: Alzheimer’s disease (AD) cerebrospinal fluid (CSF) core biomarkers (Aβ42/40 ratio, p-tau, and t-tau) provide high diagnostic accuracy, even at the earliest stage of disease. However, these markers do not fully reflect the complex AD pathophysiology. Recent large scale CSF proteomic studi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Paciotti, Silvia, Wojdała, Anna Lidia, Bellomo, Giovanni, Toja, Andrea, Chipi, Elena, Piersma, Sander R., Pham, Thang V., Gaetani, Lorenzo, Jimenez, Connie R., Parnetti, Lucilla, Chiasserini, Davide
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10350263/ https://www.ncbi.nlm.nih.gov/pubmed/37454217 http://dx.doi.org/10.1186/s13195-023-01269-8

Ejemplares similares

Phosphatidylethanolamine Binding Protein 1 (PEBP1) in Alzheimer’s Disease: ELISA Development and Clinical Validation
por: Wojdała, Anna Lidia, et al.
Publicado: (2022)

Measurement of CSF core Alzheimer disease biomarkers for routine clinical diagnosis: do fresh vs frozen samples differ?
por: Bellomo, Giovanni, et al.
Publicado: (2020)

Neuroinflammation and Alzheimer’s Disease: A Machine Learning Approach to CSF Proteomics
por: Gaetani, Lorenzo, et al.
Publicado: (2021)

Machine Learning Driven Profiling of Cerebrospinal Fluid Core Biomarkers in Alzheimer’s Disease and Other Neurological Disorders
por: Bellomo, Giovanni, et al.
Publicado: (2021)

No diurnal variation of classical and candidate biomarkers of Alzheimer’s disease in CSF
por: Cicognola, Claudia, et al.
Publicado: (2016)

CSF neurochemical profile and cognitive changes in Parkinson’s disease with mild cognitive impairment
por: Paolini Paoletti, Federico, et al.
Publicado: (2023)

The Challenge of Disease-Modifying Therapies in Parkinson’s Disease: Role of CSF Biomarkers
por: Paolini Paoletti, Federico, et al.
Publicado: (2020)

Preanalytical Confounding Factors in the Analysis of Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease: The Issue of Diurnal Variation
por: Cicognola, Claudia, et al.
Publicado: (2015)

Cerebrospinal fluid biomarkers for the diagnosis and prognosis of Parkinson’s disease: protocol for a systematic review and individual participant data meta-analysis
por: Eusebi, Paolo, et al.
Publicado: (2017)

Biomarker-Based Signature of Alzheimer’s Disease in Pre-MCI Individuals
por: Chipi, Elena, et al.
Publicado: (2019)

Diagnostic utility of CSF α-synuclein species in Parkinson's disease: protocol for a systematic review and meta-analysis
por: Eusebi, Paolo, et al.
Publicado: (2016)

Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer’s and Parkinson’s disease
por: Sjödin, Simon, et al.
Publicado: (2019)

Are We Ready for Detecting α-Synuclein Prone to Aggregation in Patients? The Case of “Protein-Misfolding Cyclic Amplification” and “Real-Time Quaking-Induced Conversion” as Diagnostic Tools
por: Paciotti, Silvia, et al.
Publicado: (2018)

Cognitive impairment in multiple sclerosis: lessons from cerebrospinal fluid biomarkers
por: Gaetani, Lorenzo, et al.
Publicado: (2020)

Increased levels of CSF total but not oligomeric or phosphorylated forms of alpha-synuclein in patients diagnosed with probable Alzheimer’s disease
por: Majbour, Nour K., et al.
Publicado: (2017)

New CSF biomarkers on the block
por: Teunissen, Charlotte E, et al.
Publicado: (2016)

Prevalence and risk of progression of preclinical Alzheimer’s disease stages: a systematic review and meta-analysis
por: Parnetti, Lucilla, et al.
Publicado: (2019)

Should CSF Biomarkers Support a Routine Analysis for Early Diagnosis of Alzheimer's Disease?
por: Parnetti, Lucilla, et al.
Publicado: (2010)

Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer’s disease core biomarkers in Lewy body disorders and Alzheimer’s dementia
por: Chiasserini, Davide, et al.
Publicado: (2017)

A/T/(N) Profile in Cerebrospinal Fluid of Parkinson’s Disease with/without Cognitive Impairment and Dementia with Lewy Bodies
por: Bellomo, Giovanni, et al.
Publicado: (2020)

Dynamic changes of CSF clusterin levels across the Alzheimer’s disease continuum
por: Tang, Lian, et al.
Publicado: (2022)

Cerebrospinal fluid lipoproteins inhibit α-synuclein aggregation by interacting with oligomeric species in seed amplification assays
por: Bellomo, Giovanni, et al.
Publicado: (2023)

The Contribution of Small Vessel Disease to Neurodegeneration: Focus on Alzheimer’s Disease, Parkinson’s Disease and Multiple Sclerosis
por: Paolini Paoletti, Federico, et al.
Publicado: (2021)

Selective loss of glucocerebrosidase activity in sporadic Parkinson’s disease and dementia with Lewy bodies
por: Chiasserini, Davide, et al.
Publicado: (2015)

Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease
por: Parnetti, Lucilla, et al.
Publicado: (2014)

Lysosomal Ceramide Metabolism Disorders: Implications in Parkinson’s Disease
por: Paciotti, Silvia, et al.
Publicado: (2020)

Factors Influencing the Measurement of Lysosomal Enzymes Activity in Human Cerebrospinal Fluid
por: Persichetti, Emanuele, et al.
Publicado: (2014)

Unraveling Pathophysiological Mechanisms of Parkinson’s Disease: Contribution of CSF Biomarkers
por: Farotti, Lucia, et al.
Publicado: (2020)

Longitudinal stability of urinary extracellular vesicle protein patterns within and between individuals
por: Erozenci, Leyla A., et al.
Publicado: (2021)

Insights into the Pathophysiology of Psychiatric Symptoms in Central Nervous System Disorders: Implications for Early and Differential Diagnosis
por: Menculini, Giulia, et al.
Publicado: (2021)

Tracing Neurological Diseases in the Presymptomatic Phase: Insights From Neurofilament Light Chain
por: Gaetani, Lorenzo, et al.
Publicado: (2021)

Alpha and Beta Synucleins: From Pathophysiology to Clinical Application as Biomarkers
por: Barba, Lorenzo, et al.
Publicado: (2022)

Evidence for Elevated Cerebrospinal Fluid ERK1/2 Levels in Alzheimer Dementia
por: Spitzer, Philipp, et al.
Publicado: (2011)

Proteomic Profiling of Mycobacterium tuberculosis Identifies Nutrient-starvation-responsive Toxin–antitoxin Systems
por: Albrethsen, Jakob, et al.
Publicado: (2013)

Characterization of Brain Lysosomal Activities in GBA-Related and Sporadic Parkinson’s Disease and Dementia with Lewy Bodies
por: Moors, Tim E., et al.
Publicado: (2018)

CSF Biomarkers Profile in CADASIL—A Model of Pure Vascular Dementia: Usefulness in Differential Diagnosis in the Dementia Disorder
por: Formichi, Patrizia, et al.
Publicado: (2010)

Cerebrospinal fluid in Alzheimer's: A precious tool
por: Parnetti, Lucilla, et al.
Publicado: (2016)

Synaptic Dysfunction in Multiple Sclerosis: A Red Thread from Inflammation to Network Disconnection
por: Bellingacci, Laura, et al.
Publicado: (2021)

HIV-Dementia Scale as a screening tool for the detection of subcortical cognitive deficits: validation of the Italian version
por: Montanucci, C., et al.
Publicado: (2021)

Re-assessment of the high-grade serous ovarian cancer phosphoproteome – Identification of kinase candidates in TCGA tumors for future clinical intervention
por: Rolfs, Frank, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_3sjo6gqlk4fvf3gcl2msd81vb4